Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Grebien Florian,

** = Publikationen gelistet in SCI/SSCI/Pubmed

2019

Zeitschriftenaufsatz

** Liberante, FG; Lappin, K; Barros, EM; Vohhodina, J; Grebien, F; Savage, KI; Mills, KI (2019): Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability. Sci Rep. 2019; 9(1):2678
Open Access Logo

** Maurer, B; Nivarthi, H; Wingelhofer, B; Pham, HTT; Schlederer, M; Suske, T; Grausenburger, R; Schiefer, AI; Prchal-Murphy, M; Chen, D; Winkler, S; Merkel, O; Kornauth, C; Hofbauer, M; Hochgatterer, B [and 23 others] (2019): High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica. 2019;
Open Access Logo [Article in Press]

** Mian, AA; Baumann, I; Liebermann, M; Grebien, F; Superti-Furga, G; Ruthardt, M; Ottmann, OG; Hantschel, O (2019): The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis. Leukemia. 2019;
Open Access Logo [Article in Press]

** Schmidt, L; Heyes, E; Scheiblecker, L; Eder, T; Volpe, G; Frampton, J; Nerlov, C; Valent, P; Grembecka, J; Grebien, F (2019): CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. Leukemia. 2019;
[Article in Press]

** Skucha, A; Ebner, J; Grebien, F (2019): Roles of SETD2 in Leukemia-Transcription, DNA-Damage, and Beyond. Int J Mol Sci. 2019; 20(5): 1029.
Open Access Logo

** Volpe, G; Cauchy, P; Walton, DS; Ward, C; Blakemore, D; Bayley, R; Clarke, ML; Schmidt, L; Nerlov, C; Garcia, P; Dumon, S; Grebien, F; Frampton, J (2019): Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations. Life Sci Alliance. 2019; 2(2):201800207.
Open Access Logo

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Menzl, I; Zhang, T; Grausenburger, R; Bauer, K; Grebien, F; Valent, P; Zuber, J; Gray, N; Sexl, V (2019): CDK8 degradation – preparing the ground for mTOR inhibition in ALL. -AEK Congress 2019; Feb 27 - MAR 1, 2019; Heidelberg, Germany.

2018

Zeitschriftenaufsatz

** Pham, HTT; Maurer, B; Prchal-Murphy, M; Grausenburger, R; Grundschober, E; Javaheri, T; Nivarthi, H; Boersma, A; Kolbe, T; Elabd, M; Halbritter, F; Pencik, J; Kazemi, Z; Grebien, F; Hengstschläger, M [and 9 others] (2018): STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018; 128(1):387-401
Open Access Logo

** Skucha, A; Ebner, J; Grebien, F (2018): SETD2 in MLL-rearranged leukemia - a complex case. Mol Cell Oncol. 2018; 5(4):e1503492

** Skucha, A; Ebner, J; Schmöllerl, J; Roth, M; Eder, T; César-Razquin, A; Stukalov, A; Vittori, S; Muhar, M; Lu, B; Aichinger, M; Jude, J; Müller, AC; Győrffy, B; Vakoc, CR [and 5 others] (2018): MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nat Commun. 2018; 9(1):1983
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Ebner, J; Skucha, A; Grebien, F (2018): Functional Investigation of SETD2 in acute myeloid leukemia. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, Austria, SEP 28 - OCT 2, 2018. Oncol Res Treat (41), S4 79-80.

** Heyes, E; Schmidt, L; Eder, T; Volpe, G; Chatziathanasiou, K; Schmidt, C; Frampton, J; Grebien, F (2018): Functional cooperation of CEBPA and TET2 mutations in Acute Myeloid Leukemia. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, Austria, SEP 28 - OCT 2, 2018. Oncol Res Treat (41), S4 40-40.

** Schmidt, L; Heyes, E; Scheiblecker, L; Eder, T; Volpe, G; Frampton, J; Nerlov, C; Valent, P; Grembecka, J; Grebien, F (2018): CEBPA-mutant acute myeloid leukemia is sensitive to small-molecule-mediated inhibition of the Menin-MLL interaction. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, Vienna, Austria, SEP 28 - OCT 2, 2018. Oncol Res Treat (41), S4 9-9.

** Schmoellerl, J; Barbosa, I; Van der Veen, C; Eder, T; Schmidt, L; Brandstoetter, T; Maurer, B; Terlecki, S; Hormann, G; Valent, P; Jude, J; Sexl, V; Zuber, J; Grebien, F (2018): NUP98-rearranged acute myeloid leukemia expresses high levels of CDK6 and is hypersensitive to Palbociclib treatment. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, Austria, SEP 28 - OCT 2, 2018. Oncol Res Treat (41), S4 40-40.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Menzl, I; Zhang, T; Grausenburger, R; Bauer, K; Grebien, F; Kubicek, S; Valent, P; Zuber, J; Gray, N; Sexl, V (2018): CDK8 degradation - Preparing the ground for mTOR inhibition in BCR/ABL+ ALL. -23rd Congress of the European Hematogloy Association; JUNI 14-17, 2018; Stockholm, Sweden. Open Access Logo

2017

Zeitschriftenaufsatz

** Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Hoermann, G; Grebien, F; Eisenwort, G; Schgoer, W; Herndlhofer, S; Kaun, C; Theurl, M; Sperr, WR; Rix, U; Sadovnik, I; Jilma, B; Schernthaner, GH [and 5 others] (2017): Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017; 31(11):2388-2397
Open Access Logo

** Noack, K; Mahendrarajah, N; Hennig, D; Schmidt, L; Grebien, F; Hildebrand, D; Christmann, M; Kaina, B; Sellmer, A; Mahboobi, S; Kubatzky, K; Heinzel, T; Krämer, OH (2017): Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells. Arch Toxicol. 2017; 91(5):2191-2208

2016

** Eder, T; Grebien, F; Rattei, T (2016): NVT: a fast and simple tool for the assessment of RNA-seq normalization strategies. Bioinformatics. 2016; 32(23):3682-3684
Open Access Logo

** Javaheri, T; Kazemi, Z; Pencik, J; Pham, HT; Kauer, M; Noorizadeh, R; Sax, B; Nivarthi, H; Schlederer, M; Maurer, B; Hofbauer, M; Aryee, DN; Wiedner, M; Tomazou, EM; Logan, M [and 10 others] (2016): Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation. Cell Death Dis. 2016; 7(10):e2419
Open Access Logo

** Pencik, J; Pham, HT; Schmoellerl, J; Javaheri, T; Schlederer, M; Culig, Z; Merkel, O; Moriggl, R; Grebien, F; Kenner, L (2016): JAK-STAT signaling in cancer: From cytokines to non-coding genome. Cytokine. 2016; 87:26-36
Open Access Logo

2015

** Grebien, F; Vedadi, M; Getlik, M; Giambruno, R; Grover, A; Avellino, R; Skucha, A; Vittori, S; Kuznetsova, E; Smil, D; Barsyte-Lovejoy, D; Li, F; Poda, G; Schapira, M; Wu, H [and 16 others] (2015): Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nat Chem Biol. 2015; 11(8):571-578
Open Access Logo

** Pencik, J; Schlederer, M; Gruber, W; Unger, C; Walker, SM; Chalaris, A; Marié, IJ; Hassler, MR; Javaheri, T; Aksoy, O; Blayney, JK; Prutsch, N; Skucha, A; Herac, M; Krämer, OH [and 25 others] (2015): STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun. 2015; 6:7736
Open Access Logo

2014

** Grundschober, E; Hoelbl-Kovacic, A; Bhagwat, N; Kovacic, B; Scheicher, R; Eckelhart, E; Kollmann, K; Keller, M; Grebien, F; Wagner, KU; Levine, RL; Sexl, V (2014): Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2. Leukemia. 2014; 28(9):1918-1922
Open Access Logo

2013

** Giambruno, R; Grebien, F; Stukalov, A; Knoll, C; Planyavsky, M; Rudashevskaya, EL; Colinge, J; Superti-Furga, G; Bennett, KL (2013): Affinity purification strategies for proteomic analysis of transcription factor complexes. J Proteome Res. 2013; 12(9):4018-4027

** Li, J; Bennett, K; Stukalov, A; Fang, B; Zhang, G; Yoshida, T; Okamoto, I; Kim, JY; Song, L; Bai, Y; Qian, X; Rawal, B; Schell, M; Grebien, F; Winter, G [and 6 others] (2013): Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol. 2013; 9:705

2012

** Hantschel, O; Grebien, F; Superti-Furga, G (2012): The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res. 2012; 72(19):4890-4895

** Hantschel, O; Warsch, W; Eckelhart, E; Kaupe, I; Grebien, F; Wagner, KU; Superti-Furga, G; Sexl, V (2012): BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol. 2012; 8(3):285-293

** Haura, EB; Sacco, R; Li, J; Müller, AC; Grebien, F; Superti-Furga, G; Bennett, KL (2012): Optimisation of Downscaled Tandem Affinity Purifications to Identify Core Protein Complexes. J Integr OMICS (2), 1 55-68.

** Winter, GE; Rix, U; Carlson, SM; Gleixner, KV; Grebien, F; Gridling, M; Müller, AC; Breitwieser, FP; Bilban, M; Colinge, J; Valent, P; Bennett, KL; White, FM; Superti-Furga, G (2012): Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol. 2012; 8(11):905-912

2011

** Grebien, F; Hantschel, O; Wojcik, J; Kaupe, I; Kovacic, B; Wyrzucki, AM; Gish, GD; Cerny-Reiterer, S; Koide, A; Beug, H; Pawson, T; Valent, P; Koide, S; Superti-Furga, G (2011): Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell. 2011; 147(2):306-319

** Hantschel, O; Grebien, F; Superti-Furga, G (2011): Targeting allosteric regulatory modules in oncoproteins: "drugging the undruggable". Oncotarget. 2011; 2(11):828-829

** Haura, EB; Müller, A; Breitwieser, FP; Li, J; Grebien, F; Colinge, J; Bennett, KL (2011): Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer. J Proteome Res. 2011; 10(1):182-190

2010

** Baumann, CL; Aspalter, IM; Sharif, O; Pichlmair, A; Blüml, S; Grebien, F; Bruckner, M; Pasierbek, P; Aumayr, K; Planyavsky, M; Bennett, KL; Colinge, J; Knapp, S; Superti-Furga, G (2010): CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med. 2010; 207(12):2689-2701

** Hoelbl, A; Schuster, C; Kovacic, B; Zhu, B; Wickre, M; Hoelzl, MA; Fajmann, S; Grebien, F; Warsch, W; Stengl, G; Hennighausen, L; Poli, V; Beug, H; Moriggl, R; Sexl, V (2010): Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med. 2010; 2(3):98-110
Open Access Logo

** Wojcik, J; Hantschel, O; Grebien, F; Kaupe, I; Bennett, KL; Barkinge, J; Jones, RB; Koide, A; Superti-Furga, G; Koide, S (2010): A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol. 2010; 17(4):519-527

2008

** Filippakopoulos, P; Kofler, M; Hantschel, O; Gish, GD; Grebien, F; Salah, E; Neudecker, P; Kay, LE; Turk, BE; Superti-Furga, G; Pawson, T; Knapp, S (2008): Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell. 2008; 134(5):793-803

** Grebien, F; Kerenyi, MA; Kovacic, B; Kolbe, T; Becker, V; Dolznig, H; Pfeffer, K; Klingmüller, U; Müller, M; Beug, H; Müllner, EW; Moriggl, R (2008): Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood. 2008; 111(9):4511-4522
Open Access Logo

** Kerenyi, MA; Grebien, F; Gehart, H; Schifrer, M; Artaker, M; Kovacic, B; Beug, H; Moriggl, R; Müllner, EW (2008): Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. Blood. 2008; 112(9):3878-3888

** Kornfeld, JW; Grebien, F; Kerenyi, MA; Friedbichler, K; Kovacic, B; Zankl, B; Hoelbl, A; Nivarti, H; Beug, H; Sexl, V; Muller, M; Kenner, L; Mullner, EW; Gouilleux, F; Moriggl, R (2008): The different functions of Stat5 and chromatin alteration through Stat5 proteins. Front Biosci. 2008; 13:6237-6254
Open Access Logo

2006

** Dolznig, H; Grebien, F; Deiner, EM; Stangl, K; Kolbus, A; Habermann, B; Kerenyi, MA; Kieslinger, M; Moriggl, R; Beug, H; Müllner, EW (2006): Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR. Oncogene. 2006; 25(20):2890-2900

2005

** Grebien, F; Dolznig, H; Beug, H; Mullner, EW (2005): Cell size control: new evidence for a general mechanism. Cell Cycle (4), 3 418-421.

2004

** Dolznig, H; Grebien, F; Sauer, T; Beug, H; Müllner, EW (2004): Evidence for a size-sensing mechanism in animal cells. Nat Cell Biol. 2004; 6(9):899-905

© Veterinärmedizinische Universität Wien Hilfe und Downloads